Eur Rev Med Pharmacol Sci 2023; 27 (13): 6081-6091
DOI: 10.26355/eurrev_202307_32962

Incidence of cereblon protein in intensive care patients: a cross-sectional study

P. Ayvat, G. Diniz, H. Gulmez, D. Arslan Yurtlu, K. Asar, K. Katircioglu, C. Ece, Z. Sofuoglu

Department of Anesthesiology, Izmir Democracy University, School of Medicine, Izmir, Turkey. pinar.ayvat@idu.edu.tr


OBJECTIVE: Sepsis remains a common cause of death. The cereblon (CRBN) protein, which is involved in important cellular processes, plays a role in sepsis. This cross-sectional study aimed to show the CRBN protein expression and its effects on patients in the intensive care unit.

PATIENTS AND METHODS: Samples were taken by deep tracheal aspiration from patients. The presence of CRBN was pathologically investigated using immunohistochemical tests and polyclonal antibodies against CRBN. The relationship between gender, sepsis, steroid, survival and the presence of CRBN was examined.

RESULTS: Respiratory and neurologic diseases were the most common reasons for admission. Acinetobacter was the most frequent microorganism. In patients with more than normal inflammatory cells, a negative correlation was observed between CRBN expression and leukocyte rate (p=0.031). In patients with CRBN, there was no correlation between steroid and mortality, APACHE/Glasgow score, hospital stay length, and ICU.

CONCLUSIONS: Although the prognosis for sepsis is better in CRBN-deficiency animals, the presence of CRBN in humans does not affect it. In our study, CRBN decreased as inflammatory cells increased in the patient’s aspiration material. The response to steroids, an immunomodulator, did not change with the presence of the immunomodulator target molecule, CRBN. Therefore, using immunomodulators in the treatment of sepsis should be reconsidered.

Free PDF Download

To cite this article

P. Ayvat, G. Diniz, H. Gulmez, D. Arslan Yurtlu, K. Asar, K. Katircioglu, C. Ece, Z. Sofuoglu
Incidence of cereblon protein in intensive care patients: a cross-sectional study

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 13
Pages: 6081-6091
DOI: 10.26355/eurrev_202307_32962